Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Gilead Sciences Inc. pages available for free this week:
- Income Statement
- Analysis of Profitability Ratios
- Analysis of Liquidity Ratios
- Common Stock Valuation Ratios
- Enterprise Value (EV)
- Dividend Discount Model (DDM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Return on Equity (ROE) since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Gilead Sciences Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Short-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The operational efficiency of the entity demonstrates a general decline over the analyzed period, characterized by an expansion of the cash conversion cycle and a slowing of inventory movement. While some metrics exhibit periodic volatility, the overarching trend indicates an increase in the time required to convert operational inputs into cash, suggesting a gradual reduction in short-term asset liquidity.
- Inventory Management Efficiency
- A downward trend is observed in inventory turnover, which declined from 4.50 in early 2022 to 3.21 by March 2026. This is mirrored by the average inventory processing period, which expanded from 81 days to 114 days. These figures indicate that inventory is remaining in stock for longer durations, potentially pointing to slowing demand or an increase in safety stock levels.
- Receivables and Collection Performance
- Receivables turnover has experienced moderate volatility, starting at 7.18 and ending at 6.17. The average receivable collection period lengthened from 51 days to 59 days over the period. Although there were periods of relative stability, the general trend indicates a slower recovery of credit sales, which contributes to the overall lengthening of the operating cycle.
- Payables and Disbursement Trends
- Payables turnover and the average payables payment period exhibit significant volatility. The payment period fluctuated between a low of 29 days and a peak of 58 days. These erratic movements suggest inconsistent payment strategies or large, periodic settlements rather than a steady disbursement schedule.
- Operating and Cash Conversion Cycles
- The operating cycle shows a consistent upward trajectory, increasing from 132 days to 173 days. Consequently, the cash conversion cycle expanded from 100 days to 135 days. This extension indicates that more working capital is tied up in the operating process, reducing the speed at which the entity regenerates cash from its investments in inventory and receivables.
- Working Capital Utilization
- Working capital turnover exhibits extreme instability, characterized by an anomalous peak of 84.15 in June 2023 followed by a significant contraction to 3.19 by March 2026. This volatility suggests substantial fluctuations in the net working capital base relative to the volume of activity generated.
Turnover Ratios
Average No. Days
Inventory Turnover
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Cost of goods sold | |||||||||||||||||||||||
| Inventories | |||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Inventory turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Inventory Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Inventory turnover
= (Cost of goods soldQ1 2026
+ Cost of goods soldQ4 2025
+ Cost of goods soldQ3 2025
+ Cost of goods soldQ2 2025)
÷ Inventories
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of short-term operating activity indicates a general decline in inventory efficiency over the period from March 31, 2022, to March 31, 2026. While the company maintained higher turnover rates in the first half of 2022, a downward trend emerged and persisted, culminating in the lowest recorded turnover ratio by the end of the analyzed period.
- Cost of Goods Sold (COGS) Trends
- Expenditures for cost of goods sold remained relatively stable, generally fluctuating between 1.4 billion and 1.6 billion US dollars. A notable anomaly occurred on December 31, 2023, where COGS spiked to 2.09 billion US dollars, representing the highest quarterly expenditure in the series. Following this peak, the values returned to the baseline range, ending at 1.445 billion US dollars in March 2026.
- Inventory Level Fluctuations
- Inventory holdings exhibited a steady upward trajectory during the first half of the observation period. Starting at 1.482 billion US dollars in March 2022, balances grew to a peak of 2.026 billion US dollars by June 30, 2024. Although a slight contraction occurred in late 2024, inventory levels remained elevated compared to 2022 levels, closing at 1.914 billion US dollars in March 2026.
- Inventory Turnover Ratio Analysis
- The inventory turnover ratio experienced a significant contraction, moving from a peak of 4.71 in September 2022 to 3.21 by March 2026. This decline suggests a slowing rate of inventory replacement. Between June 2023 and December 2025, the ratio entered a period of relative stagnation, fluctuating within a narrow band between 3.33 and 3.66. The compression of this ratio is primarily attributable to the increase in total inventory assets outpacing the growth in cost of goods sold.
- Operational Efficiency Insights
- The divergence between rising inventory levels and stagnant COGS has led to a reduction in operating efficiency regarding asset utilization. The most recent data point in March 2026 reflects the lowest turnover efficiency of the entire period, indicating that goods are remaining in stock longer than they were in the previous fiscal years.
Receivables Turnover
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Product sales | |||||||||||||||||||||||
| Accounts receivable, net | |||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Receivables turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Receivables Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Receivables turnover
= (Product salesQ1 2026
+ Product salesQ4 2025
+ Product salesQ3 2025
+ Product salesQ2 2025)
÷ Accounts receivable, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The receivables turnover ratio for the period from March 31, 2022, to March 31, 2026, demonstrates a cyclical pattern characterized by periodic declines followed by recoveries in collection efficiency. While product sales generally maintained an upward trajectory over the long term, the efficiency with which receivables were converted into cash fluctuated, reflecting shifts in the balance between revenue growth and the growth of outstanding receivables.
- 2022 Performance Trend
- A consistent decline in the receivables turnover ratio was observed throughout 2022, falling from a peak of 7.18 in March to 5.65 by December. This contraction aligns with a significant increase in net accounts receivable, which grew from $3,787 million to $4,777 million over the same period, indicating a slower rate of collection relative to sales growth.
- 2023 to 2024 Stabilization and Recovery
- Following the 2022 low, the ratio showed signs of stabilization in early 2023, reaching 6.43. Although a subsequent dip occurred in late 2023, a sustained recovery trend emerged throughout 2024, with the ratio climbing from 5.84 in March to 6.47 in December. This improvement was supported by a reduction in net accounts receivable from $4,669 million to $4,420 million, even as product sales increased.
- 2025 to 2026 Volatility and Current Status
- In 2025, the ratio experienced renewed downward pressure, reaching a period low of 5.60 in September. This decline coincided with a peak in accounts receivable of $5,095 million. However, a recovery began in the final quarter of 2025 and continued into March 31, 2026, where the ratio rose to 6.17.
- Long-term Efficiency Observation
- The overall trend suggests that while the company maintains a consistent turnover rate, there is a recurring pattern of receivable accumulation that periodically dampens the turnover ratio. The most recent data indicates a trend toward improved operational efficiency in managing short-term credit as the ratio trends upward toward the end of the analyzed period.
Payables Turnover
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Cost of goods sold | |||||||||||||||||||||||
| Accounts payable | |||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Payables turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Payables Turnover, Competitors2 | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Payables turnover
= (Cost of goods soldQ1 2026
+ Cost of goods soldQ4 2025
+ Cost of goods soldQ3 2025
+ Cost of goods soldQ2 2025)
÷ Accounts payable
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The payables turnover ratio exhibits significant volatility over the observed period, characterized by cyclical fluctuations rather than a consistent linear trend. These variations correlate closely with periodic shifts in accounts payable balances relative to the cost of goods sold, indicating fluctuating supplier payment cycles.
- Trend Analysis 2022-2023
- The initial period began with relative stability, with ratios maintained above 11.0 until a sharp contraction to 6.25 occurred on December 31, 2022. This decline was directly linked to a substantial increase in accounts payable, which peaked at 905 million USD. A recovery phase followed throughout 2023, with the ratio ascending to 11.81 by year-end. This recovery was supported by a reduction in accounts payable to 550 million USD and a significant spike in cost of goods sold to 2.09 billion USD in the final quarter of 2023.
- Trend Analysis 2024-2026
- In the first half of 2024, the turnover ratio reached a period high of 12.57 in June. However, a secondary downturn occurred in the second half of the year, with the ratio dropping to 7.49 and 7.50 in September and December, respectively. This coincided with another surge in accounts payable to 903 million USD in September 2024. From 2025 through early 2026, the ratio demonstrated a moderating pattern, fluctuating between 7.66 and 10.65, suggesting a return toward a more normalized payment cadence.
- Operational Correlation
- An inverse relationship between accounts payable levels and the turnover ratio is consistently observable. Periods of lower turnover, such as those seen in late 2022 and late 2024, align with peaks in accounts payable, indicating a lengthening of the payment period. Conversely, higher turnover ratios align with lower payable balances or increased cost of goods sold, reflecting more rapid settlement of supplier obligations.
Working Capital Turnover
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Current assets | |||||||||||||||||||||||
| Less: Current liabilities | |||||||||||||||||||||||
| Working capital | |||||||||||||||||||||||
| Product sales | |||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Working capital turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Working capital turnover
= (Product salesQ1 2026
+ Product salesQ4 2025
+ Product salesQ3 2025
+ Product salesQ2 2025)
÷ Working capital
= ( + + + )
÷ =
2 Click competitor name to see calculations.
An analysis of operating activity ratios reveals significant volatility in working capital management relative to product sales from March 2022 through March 2026. While revenue streams remained relatively stable, the working capital base experienced extreme fluctuations, resulting in an erratic working capital turnover trajectory.
- Working Capital Volatility
- Working capital exhibited substantial instability over the period. After starting at 4,071 million USD in March 2022, the figure experienced a sharp contraction to a low of 323 million USD in June 2023. Subsequently, a strong upward trend was established, with working capital expanding to 7,169 million USD by December 2024 and reaching a period peak of 9,165 million USD by March 2026.
- Product Sales Consistency
- Product sales remained comparatively steady, fluctuating between a minimum of 6,138 million USD in June 2022 and a maximum of 7,903 million USD in December 2025. The lack of dramatic shifts in sales suggests that the volatility in the turnover ratio is almost exclusively attributable to changes in current assets and liabilities rather than operational sales growth.
- Working Capital Turnover Interpretation
- The turnover ratio demonstrates a pattern of extreme spikes followed by a sustained decline. An anomalous peak of 84.15 was recorded in June 2023, directly correlating with the sharp drop in working capital. Following this event, the ratio showed another significant spike to 26.58 in March 2024. However, from September 2024 onward, a consistent downward trend is observed, with the ratio falling to 3.19 by March 2026. This decline indicates a diminishing efficiency in utilizing working capital to generate sales, as the capital base grew significantly faster than the corresponding product sales.
Average Inventory Processing Period
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Inventory turnover | |||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||
| Average inventory processing period1 | |||||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The analysis of short-term operating activity indicates a general decline in inventory management efficiency over the period from March 2022 to March 2026.
- Inventory Turnover Trends
- A consistent downward trajectory is observed in the inventory turnover ratio. The ratio began at 4.50 in March 2022 and reached a peak of 4.71 in September 2022. Following this peak, a marked decline occurred, with the ratio dropping to 3.75 by December 2022. Throughout 2023, 2024, and 2025, the turnover ratio largely fluctuated between 3.33 and 3.66. The period concludes with a minimum value of 3.21 in March 2026, indicating a reduction in the frequency with which inventory is replaced.
- Average Inventory Processing Period
- The average inventory processing period demonstrates a corresponding increase, reflecting a longer duration for inventory to be processed and sold. The period remained stable at 81 days during the first half of 2022 before rising sharply to 97 days in December 2022 and exceeding 100 days from March 2023 onward. Notable peaks occurred in June 2024 at 110 days and reached a maximum of 114 days by March 2026.
- Operational Efficiency Correlation
- A clear inverse correlation exists between the turnover ratio and the processing period. The transition from a processing period of 81 days to 114 days aligns with the decline in the turnover ratio from 4.50 to 3.21. This pattern suggests a systemic slowing of inventory throughput, resulting in a higher average age of inventory on hand and an increase in the amount of working capital tied up in stock.
Average Receivable Collection Period
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Receivables turnover | |||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||
| Average receivable collection period1 | |||||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals a fluctuating pattern in credit management and collection efficiency between March 2022 and March 2026. The inverse relationship between turnover rates and collection days indicates cyclical shifts in the speed at which outstanding receivables are converted into cash.
- Receivables Turnover Trends
- A consistent decline in turnover was observed throughout 2022, falling from 7.18 in March to 5.65 by December. Following this decline, the ratio experienced a period of instability in 2023 before demonstrating a steady recovery throughout 2024, peaking at 6.51 in March 2025. A subsequent contraction occurred in mid-2025, where the ratio dropped to 5.60 in September, before recovering to 6.17 by the end of the analyzed period in March 2026.
- Average Receivable Collection Period
- The collection period expanded from 51 days in March 2022 to 65 days by December 2022, marking a period of decreased collection efficiency. After fluctuating between 57 and 64 days during 2023, the period contracted significantly through 2024, reaching a low of 56 days by December 2024. Efficiency diminished again in 2025, with the collection period rising to 65 days by September 2025, before improving to 59 days by March 2026.
The data indicates that the most efficient collection phases occurred in early 2022 and late 2024. Conversely, the periods ending in December 2022 and September 2025 represent the points of lowest operational efficiency regarding receivable recovery, reflecting an increase in the time required to realize cash flows from credit sales.
Operating Cycle
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Average inventory processing period | |||||||||||||||||||||||
| Average receivable collection period | |||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Operating cycle1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Operating Cycle, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =
2 Click competitor name to see calculations.
The operating cycle exhibits a clear upward trajectory over the analyzed period, expanding from 132 days in March 2022 to 173 days by March 2026. This extension indicates a slower overall conversion of current assets into cash, reflecting a decrease in short-term operational efficiency.
- Average Inventory Processing Period
- A significant increase is observed in the time required to process inventory. Starting at 81 days in the first half of 2022, the period trended upward, consistently exceeding 100 days from March 2023 onwards. The peak occurred in March 2026 at 114 days. This persistent increase serves as the primary driver for the expansion of the total operating cycle.
- Average Receivable Collection Period
- The collection period demonstrates greater stability than inventory processing, though it remains higher than its initial baseline. After starting at 51 days in March 2022, the period fluctuated between a low of 55 days and a peak of 65 days. While there were periods of relative improvement—such as the dip to 56 days in December 2023—the metric generally settled in the 59-to-65 day range during the latter half of the analyzed timeframe.
- Operating Cycle Synthesis
- The total operating cycle grew by 41 days between March 2022 and March 2026. The acceleration of the cycle was most pronounced between September 2022 and December 2022, where it jumped from 137 to 162 days. The subsequent years show a pattern of stabilization at a higher plateau, with the cycle frequently oscillating between 156 and 173 days. The correlation between the inventory processing period and the total operating cycle is strong, suggesting that inventory management is the critical factor influencing the company's short-term liquidity cycle.
Average Payables Payment Period
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Payables turnover | |||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||
| Average payables payment period1 | |||||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals significant volatility in the efficiency of payables management over the observed period. Fluctuations in the average payables payment period indicate periodic shifts in the timing of supplier obligations, suggesting an inconsistent approach to short-term credit utilization.
- Payables Turnover Trends
- The payables turnover ratio exhibits a cyclical pattern with notable contractions. A significant decline is observed in December 2022, where the ratio reached a low of 6.25. While the ratio recovered to a peak of 12.57 by June 2024, subsequent declines to 7.49 and 7.50 in the latter half of 2024 indicate a recurring trend of slowing turnover. The period ending March 2026 shows a moderate recovery to 9.52, though the ratio remains unstable compared to the baseline levels seen in early 2022.
- Average Payables Payment Period Analysis
- The average time taken to settle obligations fluctuates between a minimum of 29 days and a maximum of 58 days. A primary spike occurred in December 2022, extending the payment period to 58 days, which corresponds with the lowest observed turnover ratio. A secondary period of extended payments is noted in September and December 2024, where the period stabilized at 49 days. Conversely, the company demonstrated accelerated payments in June 2024, reducing the period to 29 days.
- Operational Insights
- The inverse relationship between turnover and payment duration is consistent across all quarters. The recurring spikes in the payment period—specifically in late 2022, late 2024, and September 2025—suggest strategic or operational extensions of credit terms. The oscillation between 29 and 49 days in recent quarters reflects a lack of a stabilized payment policy, indicating that liquidity management or vendor terms are subject to frequent quarterly adjustments.
Cash Conversion Cycle
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Average inventory processing period | |||||||||||||||||||||||
| Average receivable collection period | |||||||||||||||||||||||
| Average payables payment period | |||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Cash conversion cycle1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + – =
2 Click competitor name to see calculations.
The cash conversion cycle exhibits a general upward trend over the analyzed period, indicating a lengthening of the time required to convert resource inputs into cash flows. Beginning at 100 days in March 2022, the cycle peaked at 143 days in June 2024 before settling at 135 days by March 2026. This expansion suggests a decline in short-term operating efficiency, primarily driven by an increase in the time inventory remains held before sale.
- Average Inventory Processing Period
- A consistent long-term increase is observed in the inventory processing period, rising from 81 days in early 2022 to 114 days by March 2026. There was a notable step-up in duration starting in December 2022, where the period climbed from 78 to 97 days. Throughout 2023 and 2024, the period generally remained above 100 days, reflecting a slower turnover of inventory and potentially higher stockpiling or slower sales velocity.
- Average Receivable Collection Period
- The collection period demonstrates relative stability compared to other metrics, although it shifted upward from an initial 51 days to fluctuate between 56 and 65 days. The period peaked at 65 days in December 2022 and June 2025. While the fluctuations are moderate, the overall shift suggests a slightly slower recovery of receivables from customers over the four-year span.
- Average Payables Payment Period
- Payment dynamics are characterized by significant volatility. The period fluctuated between a low of 29 days in June 2024 and a peak of 58 days in December 2022. Periodic spikes, such as those seen in late 2022 and late 2024, indicate instances where the company extended its payment obligations. However, these spikes were frequently followed by sharp contractions, suggesting inconsistent supplier payment strategies or the settlement of large periodic liabilities.
The overall deterioration of the cash conversion cycle is primarily attributed to the widening gap between inventory processing and payables payment. While the company occasionally extended its payables period to mitigate cash outflows, these actions were insufficient to offset the structural increase in inventory holding times. Consequently, the operating cycle has become more capital-intensive, requiring more working capital to support the same level of operational activity.